Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
| Revenue (TTM) | $6.10B |
| Gross Profit (TTM) | $3.27B |
| EBITDA | $1.55B |
| Operating Margin | 23.20% |
| Return on Equity | 20.30% |
| Return on Assets | 5.59% |
| Revenue/Share (TTM) | $23.33 |
| Book Value | $4.54 |
| Price-to-Book | 3.04 |
| Price-to-Sales (TTM) | 0.60 |
| EV/Revenue | 1.758 |
| EV/EBITDA | 8.29 |
| Quarterly Earnings Growth (YoY) | -1.60% |
| Quarterly Revenue Growth (YoY) | -1.70% |
| Shares Outstanding | $262.62M |
| Float | $243.06M |
| % Insiders | 0.46% |
| % Institutions | 82.03% |
Volatility is currently expanding
Organon (OGN) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.01 per share a year ago.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the third quarter 2026, which will be.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women's Health Collective Canada (WHCC) and the Partnership for Women's Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from Organon, have launched the Researching Information, Support, and Equity During the Menopause Transition in Canada (Can-RISE) Study. As the first national investigator-led study focused on Canadian women's experiences of menopause and the menopausal transition, Can-RISE is led by PWHR with funding support from WHCC.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OGN and any ticker you trade — then tracks every position and per-strategy win rate.
